Kathy Oubre on Strategies to Mitigate Challenges When Adopting New Payment Models
February 23rd 2024While adopting new payment models can come with challenges, there are strategies that can help oncology practices optimize their approaches, said Kathy Oubre, MS, CEO of Pontchartrain Cancer Center.
Read More
Dr Sudipto Mukherjee: Rethinking Clinical Management for Patients With ISM
February 22nd 2024Population-level data highlight varied risk profiles among patients with indolent systemic mastocytosis (ISM), highlighting the need for individualized treatment approaches, according to Sudipto Mukherjee, MD, PhD, MPH, a physician in the department of hematology and medical oncology at Cleveland Clinic.
Read More
COA's Dr Miriam Atkins: PBMs, HR 5526, and Marketplace Strategy
February 7th 2024Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance, discusses the impact of pharmacy benefit managers (PBMs) on health care costs and offers potential ways to remedy certain CMS decisions that negatively affect oncologists and their patients.
Read More
Bevey Miner: Unpacking the 21st Century Cures Act, the Role of Open Comment Periods
February 1st 2024Bevey Miner, executive vice president of health care strategy and policy, Consensus Cloud Solutions, discusses the complex landscape of proposed health care rules, and the potential impact of CMS' Advancing Interoperability and Prior Authorizations Rule.
Read More
Dr Sudipto Mukherjee Discusses Survival Outcomes Data in US Patients With ISM
January 30th 2024Sudipto Mukherjee, MD, PhD, MPH, hematology and medical oncology, Cleveland Clinic, suggests that some patients with indolent systemic mastocytosis (ISM) may be progressing at a faster rate than expected, and will need to be monitored and started on appropriate therapies.
Read More
Bevey Miner Talks Interoperability in Digital Health Policy
January 29th 2024Bevey Miner, executive vice president of health care strategy and policy, Consensus Cloud Solutions, discusses the historic progression of health information technology and the role interoperability plays in secure exchanging of patient data.
Read More
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More